Sign In
Buy CPRX
$31.49
+0 (+0%)
At Close: Jul 31, 2026
Catalyst Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
08:03am, Tuesday, 18'th Nov 2025
CORAL GABLES, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev
Connor Clark & Lunn Investment Management Ltd. Sells 66,267 Shares of Catalyst Pharmaceuticals, Inc. $CPRX
04:36am, Monday, 17'th Nov 2025
Connor Clark and Lunn Investment Management Ltd. cut its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) by 41.1% in the second quarter, according to the company in its most recent di
Allworth Financial LP Raises Stock Position in Catalyst Pharmaceuticals, Inc. $CPRX
03:33am, Monday, 17'th Nov 2025
Allworth Financial LP lifted its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) by 7,754.7% during the undefined quarter, according to its most recent filing with the Securities a
CPRX vs. ZTS: Which Stock Is the Better Value Option?
12:41pm, Thursday, 13'th Nov 2025
Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Zoetis (ZTS). But which of these two stocks is more attractive to value investors?
Wall Street Analysts Believe Catalyst (CPRX) Could Rally 51.45%: Here's is How to Trade
10:56am, Thursday, 13'th Nov 2025
The consensus price target hints at a 51.5% upside potential for Catalyst (CPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock
10:51am, Thursday, 13'th Nov 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock?
10:41am, Thursday, 13'th Nov 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2025 Earnings Call Transcript
08:36pm, Thursday, 06'th Nov 2025
Catalyst Pharmaceuticals, Inc. ( CPRX ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Michael Kalb - Executive VP, Treasurer & CFO Richard John Daly - President, CEO & Direct
Catalyst Pharmaceuticals Q3 Earnings Beat, Firdapse Revenues Rise Y/Y
11:46am, Thursday, 06'th Nov 2025
CPRX Q3 earnings and revenues beat estimates, driven by strong Firdapse and Agamree sales, while raising the full-year 2025 total revenue guidance.
Compared to Estimates, Catalyst (CPRX) Q3 Earnings: A Look at Key Metrics
07:01pm, Wednesday, 05'th Nov 2025
While the top- and bottom-line numbers for Catalyst (CPRX) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics comp
Catalyst Pharmaceutical (CPRX) Beats Q3 Earnings and Revenue Estimates
06:46pm, Wednesday, 05'th Nov 2025
Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.57 per share a year ago.
Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
04:06pm, Wednesday, 05'th Nov 2025
Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Gu
Catalyst Pharmaceuticals Recognized Among BioSpace 2026 Best Places to Work
04:03pm, Tuesday, 04'th Nov 2025
CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev
Catalyst Pharmaceuticals (CPRX) to Release Quarterly Earnings on Wednesday
03:02am, Tuesday, 04'th Nov 2025
Catalyst Pharmaceuticals (NASDAQ: CPRX - Get Free Report) is projected to issue its Q3 2025 results after the market closes on Wednesday, November 5th. Analysts expect the company to announce earnings
Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare Conference
08:03am, Monday, 03'rd Nov 2025
CORAL GABLES, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev
